This activity was originally broadcast in conjunction with the 2023 ASHP Midyear conference.
At the end of December 2023, targeted-release budesonide (Tarpeyo) was granted full FDA approval.
Program Description
Immunoglobulin A nephropathy (IgAN) is a type of glomerulonephritis that occurs when IgA deposits accumulate in the kidneys, leading to inflammation, renal damage, and, in some cases, progression to end-stage renal disease. As data for targeted therapies in clinical trials continue to emerge, pharmacists will be tasked with incorporating novel and recently approved therapies into existing treatment pathways and ensuring patient access to new treatments. Given their accessibility to patients across care settings, pharmacists can contribute to the early identification of risk factors and symptoms of IgAN to facilitate accurate diagnosis and prompt treatment initiation. This program will review the role of the pharmacist on the multidisciplinary care team in the management of patients with IgAN through the use of evidence-based treatments, recommendations for administration and monitoring, and counseling on recently available therapies. Considerations for medication adherence and education to mitigate drug interactions with recently approved therapies in IgAN will also be discussed.
Target audience: Health-system pharmacists, specialty pharmacists
Type of activity: Application
Release date: January 8, 2024
Expiration date: January 8, 2025
Time to complete activity: 1.5 hours
Learner level: Foundational
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Determine the incidence, pathogenesis, risk factors, clinical presentation, and health and economic burdens associated with immunoglobulin A nephropathy (IgAN)
- Explore the Kidney Disease Improving Global Outcomes guideline recommendations for the management of IgAN and the challenges associated with standard therapies
- Examine the mechanisms of action, safety and efficacy data, dosing, and administration of recent FDA-approved oral targeted therapies for IgAN
- Investigate effective patient education strategies, recommendations, and monitoring for evidence-based therapies for IgAN, as well as the importance of adherence and routine care to mitigate potential drug interactions and adverse effects
Darren W. Grabe, PharmD, BS
Associate Professor and Chair
Pharmacy Practice Department
Albany College of Pharmacy and Health Sciences
Albany, New York
Michelle M. Richardson, PharmD, BCPS
Special & Scientific Staff
William B. Schwartz Division of Nephrology
Assistant Professor of Medicine
Tufts Medical Center
Boston, Massachusetts
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-23-454-H01-P. The activity is available for CE credit through January 8, 2025.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Darren W. Grabe, PharmD, BS
Michelle M. Richardson, PharmD, BCPS
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Liza Patel, PharmD, RPh; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta, and Rebecca Green.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms